Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.10 USD
Change Today -0.11 / -2.61%
Volume 734.5K
CERS On Other Exchanges
Symbol
Exchange
CERS is not on other exchanges.
As of 5:20 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

cerus corp (CERS) Snapshot

Open
$4.23
Previous Close
$4.21
Day High
$4.27
Day Low
$4.07
52 Week High
01/5/15 - $7.03
52 Week Low
07/28/14 - $3.48
Market Cap
390.2M
Average Volume 10 Days
1.1M
EPS TTM
$-0.55
Shares Outstanding
95.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CERUS CORP (CERS)

cerus corp (CERS) Related Bloomberg News

View More Bloomberg News

cerus corp (CERS) Related Businessweek News

No Related Businessweek News Found

cerus corp (CERS) Details

Cerus Corporation operates as a biomedical products company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication and designed to target and inactivate blood-borne pathogens, including viruses, bacteria, and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company’s INTERCEPT Blood System for platelets is designed to inactivate blood-borne pathogens in platelets donated for transfusion; INTERCEPT Blood System for plasma is designed to inactivate blood-borne pathogens in plasma donated for transfusion; and INTERCEPT Blood System for red blood cells is designed to inactivate blood-borne pathogens in red blood cells donated for transfusion. Cerus Corporation markets its platelet and plasma systems through its direct sales force and distributors. The company has collaboration with Baxter International, Inc. for the development and commercialization of the INTERCEPT Blood System. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

144 Employees
Last Reported Date: 03/16/15
Founded in 1991

cerus corp (CERS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $495.8K
Co-Founder, Chief Medical Officer, Chief Scie...
Total Annual Compensation: $398.2K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $277.0K
President of Cerus Europe and EEMEA
Total Annual Compensation: $304.4K
Senior Vice President of Regulatory Affairs, ...
Total Annual Compensation: $315.4K
Compensation as of Fiscal Year 2013.

cerus corp (CERS) Key Developments

Cerus Corporation Provides Clinical Update of its TReatment UsE Study with the American Red Cross to Address Chikungunya and Dengue Blood Safety Risks with Pathogen Reduced Platelets

Cerus Corporation announced that the first patient has been enrolled in its TReatment UsE (TRUE) study to make the INTERCEPT Blood System for platelets available to regions in the United States with outbreaks of chikungunya and dengue virus under an Expanded Access Investigational Device Exemption (IDE). The American Red Cross is producing INTERCEPT platelet components for the study, which is being conducted in Puerto Rico. Dengue viruses are endemic to the Caribbean region, and local transmission of chikungunya virus was first confirmed there in early December 2013. Both viruses are spread by species of mosquitos endemic to tropical climates, as well as regions such as the Southeastern US. Concerns regarding possible transfusion transmission of chikungunya during the major epidemic in the Caribbean region throughout 2014 resulted in the issuance of a Puerto Rico Department of Health administrative order requiring that all blood donations be quarantined for 72 hours pending follow-up on donor history for acute infectious symptoms. As an alternative safety measure, the American Red Cross halted local platelet collections and began supplying Puerto Rico with blood components imported from the continental US. Subsequently, the American Red Cross elected to participate in the TRUE study, and has recently begun local production of INTERCEPT platelet components to supply Puerto Rico clinical trial sites. While the INTERCEPT Blood System received FDA approval in December 2014 for treatment of platelets in platelet additive solution (PAS-3), participating in the IDE study allows the American Red Cross to continue producing platelets in 100% plasma, according to its standard practice on the island. The American Red Cross is planning to use INTERCEPT treatment to replace common blood center safety measures, including bacterial detection and gamma irradiation, resulting in simplified logistics and timely release of platelet products. Cerus plans an FDA submission this year to enable INTERCEPT treatment of platelets in 100% plasma. Three Puerto Rico hospital sites are currently recruiting patients into the TRUE study, which is designed as a prospective, open label, multi-center, observational study to evaluate the safety of INTERCEPT platelets. Any patient requiring a platelet transfusion is eligible for study participation. In partnership with Cerus, AABB (formerly the American Association of Blood Banks) is providing hemovigilance training and education to hospital study sites, focusing on event identification and classification. This customized training program mirrors the data collection supported by the AABB Center for Patient Safety, which has the goal of identifying trends and best practices in order to promote patient care and safety in transfusion medicine.

Cerus Corporation Signs INTERCEPT Platelet Agreement with Karolinska University Hospital

Cerus Corporation announced that the Karolinska University Hospital (KUH) in Stockholm, has signed a three-year agreement to purchase the INTERCEPT Blood System for platelets. In addition to the three-year base term, the agreement allows for automatic annual extensions for an additional two years. Including KUH’s utilization of INTERCEPT in routine use, almost half of Sweden’s platelet supply is expected to be treated with the INTERCEPT Blood System for pathogen inactivation.

Cerus Corporation Announces Unaudited Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for the First Quarter and Full Year of 2015

Cerus Corporation announced unaudited consolidated financial results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported revenue of $9.674 million against $9.232 million a year ago. Loss from operations was $12.775 million against $7.806 million a year ago. Loss from operations before income taxes was $19.888 million against $5.807 million a year ago. Net loss was $19.993 million or $0.25 per diluted share against $5.860 million or $0.10 per diluted share a year ago. Increased operating expenses realized during the quarter and year ended December 31, 2014, relative to the same periods in 2013 were the primary drivers for the higher operating losses. Net loss was impacted by the mark-to-market adjustments of the Company's outstanding warrants to fair value. For the year, the company reported revenue of $36.503 million against $39.657 million a year ago. Loss from operations was $44.349 million against $28.299 million a year ago. Loss from operations before income taxes was $38.371 million against $43.119 million a year ago. Net loss was $38.566 million or $0.60 per diluted share against $43.337 million or $0.64 per diluted share a year ago. The lower revenue for 2014 relative to 2013 was a result of transitions to a direct sales force during 2014 in certain historical distributor geographies. Net loss was impacted by the mark-to-market adjustments of the Company's outstanding warrants to fair value. For the year, operating results were impacted by noncash gains of $7.7 million. For the first quarter of 2015 revenue is expected to decrease by at least $2 million from fourth quarter of 2014 based primarily on weakness in the Russian market, and to a lesser extent, on continued weakness in the Euro. The company anticipates cash used for operating activities will increase in 2015 to an average of $12 million to $13 million a quarter, up from the approximately $10 million a quarter the company experienced in 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CERS:US $4.10 USD -0.11

CERS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Antares Pharma Inc $2.58 USD 0.00
Cutera Inc $13.23 USD -0.07
Pluristem Therapeutics Inc $2.83 USD -0.03
STAAR Surgical Co $7.38 USD +0.13
SurModics Inc $25.96 USD +0.26
View Industry Companies
 

Industry Analysis

CERS

Industry Average

Valuation CERS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.1x
Price/Book 8.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CERUS CORP, please visit www.cerus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.